Man Group
AVIR icon

Man Group’s Atea Pharmaceuticals AVIR Stock Holding History

Man Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-57,777
Closed -$278K – 2072
2022
Q4 		$278K Sell
57,777
-10,660
-16% -$53.9K ﹤0.01% 1671
2022
Q3 		$389K Buy
+68,437
New +$524K ﹤0.01% 1593
2022
Q2 		– Sell
-42,100
Closed -$287K – 1584
2022
Q1 		$304K Sell
42,100
-35,902
-46% -$244K ﹤0.01% 1748
2021
Q4 		$697K Sell
78,002
-9,608
-11% -$150K ﹤0.01% 1434
2021
Q3 		$3.07M Buy
87,610
+74,307
+559% +$2.06M 0.01% 1032
2021
Q2 		$285K Buy
+13,303
New +$400K ﹤0.01% 1692

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's AVIR Position: Q1 2023 in Review

Man Group sold out of Atea Pharmaceuticals (AVIR) in Q1 2023, closing a stake of 57,777 shares — an estimated $278K sold.

Man Group first reported a position in AVIR in Q2 2021 and held it in 6 quarters. The position peaked at $3.07M in Q3 2021. 130 funds tracked by Wall St. Rank hold AVIR as of Q1 2023.

  • Man Group reported no remaining Atea Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Man Group sold 57,777 Atea Pharmaceuticals shares in Q1 2023, an estimated $278K.
  • Man Group first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 6 quarters.
  • Man Group's Atea Pharmaceuticals position peaked at $3.07M in Q3 2021.
  • 130 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.